Curespec offers Nephrospec™, a non-invasive electro-Hydraulic Acoustic Therapy (eHAT) device that improves kidney function and reduces hypertension by promoting neovascularization and restoring damaged renal tissue. This technology addresses chronic kidney disease and high blood pressure, potentially delaying the need for dialysis and lowering treatment costs by up to 80%.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic kidney disease (CKD) and hypertension often lead to damaged renal tissue and impaired kidney function. Current treatments may be invasive or have limited effectiveness in restoring kidney function and reducing high blood pressure, potentially leading to dialysis.
Solution
Curespec offers Nephrospec™, a non-invasive electro-Hydraulic Acoustic Therapy (eHAT) device designed to improve kidney function and reduce hypertension. The device uses low-intensity electro-hydraulic acoustic waves to promote neovascularization and restore damaged renal tissue. This therapy aims to provide a complementary solution to optimize medical care for CKD and hypertension, potentially delaying the need for dialysis and lowering associated treatment costs. The outpatient therapy is designed to be painless and radiation-free.
Target Audience
The primary target audience includes nephrologists and healthcare providers treating patients with chronic kidney disease and resistant hypertension.
Features
- Non-invasive electro-Hydraulic Acoustic Therapy (eHAT) for CKD and hypertension
- Promotes neovascularization in the kidneys
- Restores damaged renal tissue function
- Aims to improve kidney function within a few weeks
- Designed to postpone the onset of dialysis
- Reduces high blood pressure